1. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Milne GL, Sanchez SC, Musiek ES, Morrow JD (2007) Nat Protoc 2(1): 221-6
    › Primary publication · 17401357 (PubMed)
  2. In vivo oxidative damage in rats is associated with barbiturate response but not other cytochrome P450 inducers. Dostalek M, Brooks JD, Hardy KD, Milne GL, Moore MM, Sharma S, Morrow JD, Guengerich FP (2007) Mol Pharmacol 72(6): 1419-24
    › Primary publication · 17898314 (PubMed)
  3. Ibuprofen use during extreme exercise: effects on oxidative stress and PGE2. McAnulty SR, Owens JT, McAnulty LS, Nieman DC, Morrow JD, Dumke CL, Milne GL (2007) Med Sci Sports Exerc 39(7): 1075-9
    › Primary publication · 17596774 (PubMed)
  4. Energy expenditure, inflammation, and oxidative stress in steady-state adolescents with sickle cell anemia. Akohoue SA, Shankar S, Milne GL, Morrow J, Chen KY, Ajayi WU, Buchowski MS (2007) Pediatr Res 61(2): 233-8
    › Primary publication · 17237728 (PubMed)
  5. Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus. Avalos I, Chung CP, Oeser A, Milne GL, Borntrager H, Morrow JD, Raggi P, Solus J, Stein CM (2007) Lupus 16(12): 981-6
    › Primary publication · 18042592 (PubMed)
  6. Interaction of electrophilic lipid oxidation products with mitochondria in endothelial cells and formation of reactive oxygen species. Landar A, Zmijewski JW, Dickinson DA, Le Goffe C, Johnson MS, Milne GL, Zanoni G, Vidari G, Morrow JD, Darley-Usmar VM (2006) Am J Physiol Heart Circ Physiol 290(5): H1777-87
    › Primary publication · 16387790 (PubMed)
  7. Hypertrophic osteoarthropathy pathogenesis: a case highlighting the potential role for cyclo-oxygenase-2-derived prostaglandin E2. Kozak KR, Milne GL, Morrow JD, Cuiffo BP (2006) Nat Clin Pract Rheumatol 2(8): 452-6; quiz following 456
    › Primary publication · 16932737 (PubMed)
  8. Elevated oxidation of docosahexaenoic acid, 22:6 (n-3), in brain regions of rats undergoing ethanol withdrawal. Milne GL, Morrow JD, Picklo MJ (2006) Neurosci Lett 405(3): 172-4
    › Primary publication · 16875780 (PubMed)
  9. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA (2006) Clin Cancer Res 12(11 Pt 1): 3381-8
    › Primary publication · 16740761 (PubMed)
  10. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, Milne GL, Katkuri S, DuBois RN (2005) J Biol Chem 280(5): 3217-23
    › Primary publication · 15542609 (PubMed) · PMC1847633 (PubMed Central)